Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutam...

Descripción completa

Detalles Bibliográficos
Autores principales: Staniszewska, Magdalena, Fragoso Costa, Pedro, Eiber, Matthias, Klose, Jasmin M., Wosniack, Jasmin, Reis, Henning, Szarvas, Tibor, Hadaschik, Boris, Lückerath, Katharina, Herrmann, Ken, Fendler, Wolfgang P., Iking, Janette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304389/
https://www.ncbi.nlm.nih.gov/pubmed/34299051
http://dx.doi.org/10.3390/ijms22147431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304389/
https://www.ncbi.nlm.nih.gov/pubmed/34299051
http://dx.doi.org/10.3390/ijms22147431

Ejemplares similares